Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $8.20, for a total transaction of $41,000.00. Following the sale, the chief technology officer directly owned 177,171 shares of the company’s stock, valued at $1,452,802.20. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, August 24th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.80, for a total value of $44,000.00.
• On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.60, for a total value of $38,000.00.
• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.95, for a total value of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.10, for a total value of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.51, for a total value of $38,261.44.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ:SOPH opened at $8.92 on Friday. The firm has a market capitalization of $748.34 million, a PE ratio of -7.76 and a beta of 0.96. SOPHiA GENETICS SA has a 12 month low of $3.10 and a 12 month high of $8.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The business has a 50-day moving average of $6.46 and a two-hundred day moving average of $5.43.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, research analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of large investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after buying an additional 5,432,871 shares during the period. AWM Investment Company Inc. purchased a new position in SOPHiA GENETICS in the 2nd quarter valued at about $9,809,000. Akre Capital Management LLC grew its stake in shares of SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the first quarter valued at about $2,157,000. Finally, Royce & Associates LP purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter worth about $2,009,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SOPH has been the subject of a number of research reports. HC Wainwright upped their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. BTIG Research raised their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Unusual trading volume is drawing attention to SOPH, with the stock approaching a new 12-month high. The activity suggests increased investor interest and reinforces the recent upward momentum. When Unusual Volume Isn’t Noise: 3 Small-Caps Sending Signals
• Positive Sentiment: Analyst sentiment improved after the August 5 earnings report. BTIG Research raised its price target to $9 from $8, while HC Wainwright lifted its target to $14 from $12; both firms maintained Buy ratings. The reported $23.31 million in revenue exceeded the $21.72 million consensus estimate, although the company still posted a larger-than-expected quarterly loss. The average analyst price target is approximately $10.
• Neutral Sentiment: Reported short interest was zero shares as of August 25, indicating little measurable short-selling pressure, but also providing limited incremental trading information.
• Negative Sentiment: Several insiders recently sold shares: CTO Abhimanyu Verma sold 5,000 shares on August 19 and another 5,000 on August 24; Director Kathy L. Hibbs sold 6,250 shares on August 25; and Philippe Menu sold 5,000 shares on August 25. The transactions reduced their individual holdings by roughly 2% to 6% and could weigh on sentiment. However, all were executed under pre-arranged Rule 10b5-1 plans, meaning they may not represent current concerns about SOPHiA GENETICS. SEC insider transaction filing
• Negative Sentiment: SOPHiA GENETICS remains unprofitable: it reported a quarterly loss of $0.26 per share versus the $0.21 consensus loss estimate, and analysts expect a full-year loss of approximately $0.77 per share. Its negative margins and continued earnings losses remain key risks despite the revenue beat and improving share-price momentum.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.